Caris Discovery
Unlock truly novel targets for your discovery pipeline
Caris has the tools and data to help you identify, develop and commercialize your next oncology targets.
Despite transformational breakthroughs in our understanding of disease, drug development has focused on a redundant, limited number of targets. Caris Discovery is an indication and modality-agnostic discovery engine which aims to identify and validate novel targets for therapeutic development using a portfolio of innovative tools and technologies:
- Interrogation of primary patient tissue
- Proprietary aptamer-based proteomic profiling platform (ADAPT)
- Unparalleled in silico analysis
- Cutting-edge research experimentation at Caris’ dedicated 59,000 square foot research lab
Harness the power of tissue-based discovery platforms and state-of-the art lab technologies to advance the next wave of therapeutics.
“Caris Discovery is uncovering novel unexplored targets in patient populations where precision therapeutics have yet to be developed.”
—Milan Radovich, PhD, Chief Scientific Officer
Harness the Power of Tissue-Based Discovery and an Unmatched Tumor Profiling Library
>745,000 Tumor Profiles
Large Repository of Tissue Slides Available
Transformative Multimodal Data
Broad Target Discovery Platform
Novel Discovery Engine
- ADAPT Biotargeting System™
- Tissue Proximity Labeling
- Cell Surfaceome Confirmation
- Cancer-Specific Protein Enrichment
- Target Localization
Multi-Omic Insights
- Whole Exome Sequencing
- Whole Transcriptome Sequencing
- Digital Pathology and IHC Images
- Tumor Associations
- Protein Family Member Expression
Drug Development
- Protein Prevalence from Patient Tissue
- RNA-Protein Correlation
- Cell Surface Copy Number
- Target Internalization
- Drug Discovery and In Vitro Pharmacology
Longitudinal Clinical Insights
- Patient Health Records
- Claims Data (Treatments)
- Patient Survival
- Historical Rx Response
- Pre/Post Treatment Patient Grouping
First-in-Class Drug Target Identification, Validation and Development
- Identify truly novel oncology targets and increase confidence in target selection through Caris’ broad data assets.
- Collaboratively design discovery and development strategies to identify targets amenable to any modality of interest.
- Advance superior therapies through data-driven refinement, trial enablement and companion diagnostic (CDx) development, using the full breadth and depth of Caris Life Sciences suite of solutions
Platform Summary
Identify Novel Drug Targets
Tissue: Wet lab validation & characterization
Data: In silico validation & characterization
Machine Learning Predictive AI
State-of-the-Art Equipment and Facilities for Target ID and Therapeutic Development
- 50 NovaSeq Sequencers
- Largest NovaSeq sequencing lab in the U.S.
- Innovation for enhanced depth of coverage
- Maximal throughput and efficiency
Four Precision Medicine Laboratories (Phoenix and Dallas) Totaling 275,000+ Sq. FT
Clinical Blood Lab
(Cotton Center, Phoenix, AZ)
Clinical Tissue Lab
(Cotton Center, Phoenix, AZ)
Drug Target Discovery Lab
(Papago, Phoenix, AZ)
Coming Soon – Clinical Lab
(Irving, TX)
Flexible Partnering Structures to Accommodates Diverse Needs
Caris has developed a flexible partnering model to meet our partners specific needs. Whether it is a joint target discovery collaboration, target out-licensing or target validation model, Caris can structure partnerships to meet your needs.
Target Out-License
Internally discovered and fully validated novel targets
Joint Target Discovery
Partnering to jointly discover and develop therapeutic cancer targets
Target Validation
Collaborating together to validate drug targets
Discover
More
WES & WTS provide assurances to your clinical development programs with data-driven decisions.
Caris Life Sciences is at the forefront of a data-led revolution in personalized cancer care.